How to Taper Off Venlafaxine
Gradually reduce venlafaxine dose rather than stopping abruptly, using a hyperbolic (percentage-based) tapering schedule that slows as you approach lower doses, with reductions every 2-4 weeks based on patient tolerance. 1
Core Tapering Principles
The FDA label explicitly states that gradual dose reduction is recommended whenever possible rather than abrupt cessation 1. If intolerable symptoms occur during taper, resume the previous dose and then decrease more gradually 1.
Standard Tapering Approach
For Lower-Risk Patients:
- Reduce by 25-50% of current dose every 2 weeks until reaching very low doses 2
- Example: 150 mg → 75 mg (2 weeks) → 37.5 mg (2 weeks) → stop
- This approach works for patients without prior failed discontinuation attempts or significant risk factors
For Higher-Risk Patients:
Use hyperbolic (percentage-based) tapering over months, which means:
- Reduce by approximately 20-25% of the current dose every 2 weeks 3, 4
- Continue reductions down to very low doses (potentially 1-10 mg range) before complete cessation 2
- Example: 150 mg → 112.5 mg → 84 mg → 63 mg → 47 mg → 35 mg → and so on
The evidence strongly supports this approach: a 2023 prospective study of 608 patients (mostly on venlafaxine or paroxetine) found that hyperbolic tapering with daily tiny reductions (4.5% per day or 25.3% per week) produced significantly less withdrawal than weekly larger steps (33.4% per week) 3.
Risk Factors Requiring Slower Taper
Identify patients needing the slower hyperbolic approach:
- Previous failed discontinuation attempts 3
- Longer duration of therapy (>12 months) 2
- Higher doses 2, 5
- Female sex and younger age 3
- History of withdrawal symptoms 5
Venlafaxine specifically carries higher risk of withdrawal symptoms compared to other antidepressants due to its shorter half-life 2, 6.
Practical Implementation
Formulation Considerations:
- Extended-release formulations may be easier to taper initially
- For very gradual tapers reaching doses below 37.5 mg, you may need:
Monitoring Schedule:
- Follow-up every 2-4 weeks during active tapering 5
- Continue monitoring for 16 weeks after complete discontinuation 4
- At each visit, assess for withdrawal symptoms versus relapse
Critical Pitfall: Distinguishing Withdrawal from Relapse
Withdrawal symptoms typically:
- Emerge within 1-7 days of dose reduction
- Peak early and improve over 1-2 weeks
- Include physical symptoms (dizziness, electric shock sensations, nausea, headache)
- May include akathisia (inner restlessness) 5
Relapse typically:
- Emerges more gradually (weeks)
- Worsens progressively
- Matches original depressive symptoms
- Lacks prominent physical symptoms
If Withdrawal Occurs:
- Pause the taper at current dose for 2-4 weeks 5
- If symptoms severe, reinstate previous dose 1
- Once stabilized, resume tapering at slower rate (smaller decrements, longer intervals)
Special Warnings
Suicidal ideation can emerge during discontinuation, particularly with paroxetine but potentially with any antidepressant 6. Monitor closely, especially in the first weeks after dose reductions.
Protracted withdrawal (symptoms lasting months) can occur in some patients 5. These individuals may require tapering over 6-12 months or longer.
Duration of Taper
- Low-risk patients: 4-6 weeks total 2
- Higher-risk patients: 3-6 months common 2, 5
- Highest-risk patients: May require 12+ months to reach complete cessation 5
The 2023 prospective study demonstrated that slower tapering trajectories (longer duration with smaller percentage reductions) consistently produced less withdrawal across all patient groups 3.